Bausch & Lomb Stock Symbol Performance Analysis

Bausch & Lomb's stock symbol, BOL, has been publicly traded since 1967. The company's stock has undergone significant changes over the years, with its market capitalization fluctuating between $1.5 billion and $7.5 billion.

Bausch & Lomb's stock has experienced periods of high growth, particularly in the 1990s and early 2000s. During this time, the company's revenue increased by over 50% due to the success of its contact lens and eye care products.

The company's stock price has been affected by various market and economic factors, including the 2008 financial crisis. As a result, Bausch & Lomb's stock price dropped by over 50% in a single year.

Bausch & Lomb's stock has shown resilience in recent years, with a steady increase in its stock price since 2015.

Bausch & Lomb stock is trading at a significant discount to its estimated fair value, coming in at 57.5% below.

The company's earnings are expected to experience a remarkable growth rate of 58% per year, indicating a strong potential for future success.

Analysts are in good agreement that the stock price will rise by 23.1%, making it a promising investment opportunity for those who are willing to take a chance.

This level of growth and agreement among analysts suggests that Bausch & Lomb stock is worth considering for investors looking to diversify their portfolios.

Bausch + Lomb's current share price is a crucial factor to consider when evaluating the stock. As of the latest available data, the current share price is US$15.81.

The company has experienced some fluctuations in its share price over the past year, with a 1 Year Change of -6.34%. This indicates a moderate decline in value over the past 12 months.

Here's a summary of the key price and performance metrics:

The company's beta, which measures its volatility compared to the overall market, is a relatively low 0.46. This suggests that the stock may be less sensitive to market fluctuations than other stocks.

The price history of Bausch + Lomb is quite telling. The current share price is $15.81, which is a far cry from the 52-week high of $21.69. In fact, the stock has taken a beating, with a 1-month change of -8.03% and a 3-month change of -19.95%.

Let's take a look at the 52-week low, which is $13.16. This shows just how volatile the stock has been. The beta, or volatility measure, is 0.46, indicating that the stock is less volatile than the market as a whole.

Here's a quick summary of the changes in the stock price over the past year:

These numbers show that the stock has been on a downward trend, but it's not all bad news. The stock has actually increased in value over the past five years, with a change of -20.95% since the IPO.

BLCO's price volatility is worth examining.

The company's average weekly movement is 5.3%, which is lower than the medical equipment industry average movement of 7.9%. This suggests that BLCO's share price is relatively stable compared to its peers.

In comparison to the overall market, BLCO's price movement is also lower, coming in at 6.0%. This stability is a positive sign for investors.

To put BLCO's volatility into perspective, let's look at some benchmarks. The 10% most volatile stocks in the US market have an average weekly movement of 17.8%, while the 10% least volatile stocks have an average movement of 3.1%. BLCO's 5.3% movement falls well within the middle range of these two groups.

Here's a comparison of BLCO's volatility to some key benchmarks:

In the past year, BLCO's weekly volatility has remained stable at 5%. This consistency is a good sign for investors looking for a reliable stock.

BLCO stock is trading at a significant discount, 57.5% below its estimated fair value.

The company's earnings are expected to grow at a rapid pace, 58% per year, which is a promising sign for investors.

BLCO's profitability metrics paint a mixed picture, with a gross margin of 54.915%, but negative operating, pretax, net, return on assets, return on equity, return on total capital, and return on invested capital margins.

Here are BLCO's profitability metrics in detail:

Over the past year, BLCO's stock price has underperformed the US Medical Equipment industry and the broader US Market, returning -6.3% compared to 11.7% and 17.8% respectively.

BLCO's current open price is $15.78. This is a crucial metric for investors to consider when making decisions about buying or selling shares.

The company's 52-week range is between $13.16 and $21.69, giving you an idea of the stock's volatility. This range can be a good indicator of whether the stock is trending upwards or downwards.

The market capitalization of BLCO is $5.55 billion, which is a significant amount of money. This metric can give you an idea of the company's size and influence in the market.

Here is a summary of BLCO's key data:

BLCO's profitability is a mixed bag, with some positive and negative trends.

The company's gross margin is a respectable 54.915, which means it's able to keep a significant portion of its revenue after accounting for the cost of goods sold.

However, its operating margin of 4.30 is relatively low, indicating that the company is not efficiently managing its operating expenses.

BLCO's pretax margin is a concerning -4.884, suggesting that the company is losing money before taxes.

The net margin is even more alarming, at -6.617, which means the company is losing money after taxes.

The return on assets, return on equity, return on total capital, and return on invested capital are all negative, ranging from -2.356 to -2.78.

Here's a summary of BLCO's profitability in a table:

When looking at the shareholder returns of BLCO, it's clear that the company hasn't been performing well. The 7-day return shows a -3.7% decrease, which is not a great sign.

The 1-year return is even more concerning, with a -6.3% drop. This is a significant underperformance compared to the US Medical Equipment industry, which has seen a 10% return over the past year.

To put this into perspective, the US Market has returned 18.3% over the past year, which is a stark contrast to BLCO's performance.

Here's a quick comparison of BLCO's returns with the US Medical Equipment industry and the US Market:

As you can see, BLCO is significantly underperforming the US Medical Equipment industry and the US Market as a whole.

Analyst forecasts can be a valuable tool for investors looking to make informed decisions. The average rating for BLCO stock is "Buy" according to 12 analysts.

These analysts are predicting a significant increase in the stock price, with a 12-month forecast of $19.82, representing a 25.36% rise from the latest price. This suggests that the majority of analysts believe the stock has growth potential.

In fact, 5 out of 12 analysts currently have a "BUY" rating, which is the same number as 1 month ago. This indicates a level of consistency in their expectations for the stock's performance.

Here's a breakdown of the analyst recommendations:

This data provides a snapshot of the current sentiment among analysts, which can be useful for investors looking to make informed decisions about their investments.

If you're considering investing in Bausch & Lomb, it's essential to understand the company's stock performance.

The Bausch & Lomb stock symbol is BOL. This is the ticker symbol used to identify the company's shares on the New York Stock Exchange (NYSE).

Bausch & Lomb is a leading global eye health company, and its stock has historically been volatile. The stock has experienced significant fluctuations in recent years, with a high of $33.65 in 2020 and a low of $11.65 in 2019.

Investors should be aware that Bausch & Lomb has a market capitalization of around $15 billion, which can impact the stock's price and volatility.